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Abstract
BACKGROUND—A new approach in the treatment of cystic fibrosis involves improving the
function of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a
CFTR potentiator, has been shown to increase the activity of wild-type and defective cell-surface
CFTR in vitro.
METHODS—We randomly assigned 39 adults with cystic fibrosis and at least one G551D-CFTR
allele to receive oral VX-770 every 12 hours at a dose of 25, 75, or 150 mg or placebo for 14 days
(in part 1 of the study) or VX-770 every 12 hours at a dose of 150 or 250 mg or placebo for 28
days (in part 2 of the study).
RESULTS—At day 28, in the group of subjects who received 150 mg of VX-770, the median
change in the nasal potential difference (in response to the administration of a chloride-free
isoproterenol solution) from baseline was −3.5 mV (range, −8.3 to 0.5; P = 0.02 for the within-
subject comparison, P = 0.13 vs. placebo), and the median change in the level of sweat chloride
was −59.5 mmol per liter (range, −66.0 to −19.0; P = 0.008 within-subject, P = 0.02 vs. placebo).
The median change from baseline in the percent of predicted forced expiratory volume in 1 second
was 8.7% (range, 2.3 to 31.3; P = 0.008 for the within-subject comparison, P = 0.56 vs. placebo).
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None of the subjects withdrew from the study. Six severe adverse events occurred in two subjects
(diffuse macular rash in one subject and five incidents of elevated blood and urine glucose levels
in one subject with diabetes). All severe adverse events resolved without the discontinuation of
VX-770.
CONCLUSIONS—This study to evaluate the safety and adverse-event profile of VX-770
showed that VX-770 was associated with within-subject improvements in CFTR and lung
function. These findings provide support for further studies of pharmacologic potentiation of
CFTR as a means to treat cystic fibrosis.
Cystic fibrosis is a progressive lung disease1 caused by mutations in the gene encoding the
cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial ion
channel involved in salt and fluid transport in multiple organs, including the lung.2,3 Current
treatments for cystic fibrosis target the secondary effects of CFTR dysfunction. Although the
median predicted survival among patients with cystic fibrosis has improved,4 the life
expectancy of these patients remains well below normal, and the treatment burden to
maintain health is high,5 indicating a need for better therapies. A strategy with potential
advantages over current regimens involves improving defective CFTR function
systemically; this strategy aims to slow lung damage and reduce the manifestations of
extrapulmonary disease and the treatment burden.6
Some mutations permit CFTR protein to reach the epithelial-cell surface, but the protein is
defective in chloride transport.7 The most prevalent mutation of this type in patients with
cystic fibrosis causes a substitution of glycine for aspartic acid at amino acid 551 (G551D-
CFTR); this mutation occurs in approximately 4 to 5% of persons with cystic fibrosis.4
Agents that increase the ion-channel function of activated cell-surface CFTR are referred to
as “potentiators.” VX-770 is an investigational, orally bioavailable CFTR potentiator that
has been shown to increase the activity of wild-type and defective cell-surface CFTR protein
in vitro.8 The greatest effect of VX-770 was on cells with G551D-CFTR.
The primary end points of this randomized, placebo-controlled trial involving subjects with
the G551D-CFTR mutation were the safety and adverse-event profile of VX-770. Evidence
of improvement in CFTR-mediated ion transport and pulmonary status were evaluated as
secondary end points.
METHODS
Part 1 of this two-part, double-blind, placebo-controlled, multicenter, phase 2 trial had a
modified crossover design, and part 2 had a parallel design (Fig. 1 in the Supplementary
Appendix, available with the full text of this article at NEJM.org). The protocol (available at
NEJM.org) was reviewed and approved by the institutional review board in each
participating center, and each subject provided written informed consent. Subjects had to be
18 years of age or older and have cystic fibrosis,9 a G551D mutation on at least one CFTR
allele, and a forced expiratory volume in 1 second (FEV1) of 40% or more of the predicted
value for age, sex, and height.10
The first author wrote the first draft of the manuscript and made the decision to submit the
article for publication after consultation with the other authors. All authors vouch for the
accuracy and completeness of the reported data. The authors also certify that the study as
reported conforms with the protocol.
Part 1 of the study involved subjects who were randomly assigned to receive VX-770 every
12 hours at doses of 25, 75, or 150 mg or placebo. The study drug was administered during
two 14-day periods separated by a washout period. Part 2 of the study involved new subjects
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who were randomly assigned to receive VX-770 every 12 hours at a dose of 150 or 250 mg
or placebo for 28 consecutive days.
The primary objective was to evaluate the safety and adverse-event profile of VX-770.
Secondary end points included assessment of biomarkers of CFTR ion-channel function,
pulmonary function, and health-related quality of life. The CFTR chloride transport function
was evaluated in the airway epithelium on the basis of the nasal potential difference11 and
outside the respiratory tract on the basis of the sweat chloride concentration. Clinical
efficacy was evaluated on the basis of the change in the FEV1 from baseline and a disease-
specific health-related quality-of-life instrument, the Cystic Fibrosis Questionnaire–revised
(CFQ-R) (in part 2 of the study only).12 Each CFQ-R domain is scored on a 100-point scale,
with higher scores indicating a lower effect of symptoms on the patient’s quality of life. A
minimal clinically important difference of 4 points has been determined for the respiratory
symptoms domain.13
Further details of the study design, measurement of biomarkers and lung function, and the
health-related quality-of-life instrument are provided in the Supplementary Appendix.
RESULTS
SUBJECTS
Twenty subjects received a study drug in part 1 of the study, and 19 subjects received a
study drug in part 2. The baseline characteristics of the subjects are shown in Table 1. The
sex distribution was well balanced, and the body-mass index and other relevant baseline
clinical and demographic characteristics were similar between the groups in each part of the
study. The median rate of adherence to treatment was high among subjects in both parts of
the study (96.4% [range, 60.7 to 100] in part 1 and 100% [range, 92.6 to 100] in part 2).
SAFETY AND ADVERSE-EVENT PROFILE
All subjects who began to receive a study drug completed the assigned study drugs
(randomization and study-drug assignments are shown in Fig. 2 in the Supplementary
Appendix). The frequency of adverse events was similar between the groups and between
the parts of the study. Most adverse events were reported in one or two subjects in any
group, with more frequent events being fever (in four subjects in the group of subjects who
received 75 mg of VX-770); cough (in three subjects in the placebo group in part 1 of the
study and in three subjects who received 250 mg of VX-770 in part 2 of the study); and
nausea, pain, and rhinorrhea (in three subjects each in the group of subjects who received 75
mg of VX-770). All adverse events are listed in Table 1 in the Supplementary Appendix.
Adverse events that were considered moderate (grade 2) or severe (grade 3) are shown in
Table 2. Six adverse events were severe; all occurred during part 1 of the study. These
events consisted of diffuse macular rash in one subject who was receiving VX-770 at a dose
of 150 mg and an elevated blood glucose level on three occasions (two occurred within the
same treatment period and were counted once in Table 2) and urine that was positive for
glucose on two occasions in one subject over both treatment periods (VX-770 at doses of 75
mg and 150 mg). The subject in whom the macular rash developed had received intravenous
antibiotics during hospitalization to treat a mild pulmonary exacerbation. The pulmonary
exacerbation and macular rash in this subject were the only adverse events in the study that
met the definition of serious adverse events. The subject in whom elevated blood and urine
glucose levels developed had a history of insulin-dependent diabetes. All serious or severe
adverse events resolved without discontinuation of the study drug.
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We evaluated the effects of VX-770 on measurements of the potential difference across the
nasal mucosa and on the chloride concentration of sweat, both markers of CFTR function.
Figure 1 shows the nasal potential difference (in response to the administration of a
chloride-free isoproterenol solution), a measure of CFTR-mediated chloride transport. In
part 1 of the study, significant within-subject changes from baseline to day 14 were observed
in the VX-770 75-mg group (mean, −4.7 mV; 95% confidence interval [CI], −7.5 to −1.9;
P=0.003) and in the 150-mg group (mean, −5.4 mV; 95% CI, −9.3 to −1.6; P = 0.01). No
significant change from baseline was detected in the placebo group (−1.7 mV; 95% CI, −6.1
to 2.6; P = 0.41) or the VX-770 25-mg group (−1.6 mV; 95% CI, −5.6 to 2.5; P = 0.43).
None of the changes from baseline were significant as compared with the placebo group (P
= 0.95, P = 0.24, and P = 0.21 for the VX-770 25-mg, 75-mg, and 150-mg groups,
respectively). In part 2 of the study, the median within-subject change from baseline to day
28 was significant in the VX-770 150-mg group (−3.5 mV; range, −8.3 to 0.5; P = 0.02) and
the 250-mg group (−5.5 mV; range, −28.5 to 2.0; P = 0.05), but not in the placebo group
(−0.4 mV; range, −2.3 to 4.0; P = 0.88). In the VX-770 treatment groups, the changes from
baseline were not significantly different from placebo (P = 0.13 and P = 0.16 in the VX-770
150-mg and 250-mg groups, respectively). Responses in the VX-770 treatment groups were
similar to baseline values after the washout period in part 1 of the study (Fig. 3 in the
Supplementary Appendix).
After 14 days of treatment with VX-770, some subjects for whom data were available in
parts 1 and 2 of the study were considered to have had a response according to the
predefined response criterion of a decrease from baseline of 5 mV or more in the nasal
potential difference after the administration of a chloride-free isoproterenol solution. These
subjects were the following: 1 of 7 in the 25-mg group (14%), 5 of 15 in the 75-mg group
(33%), 10 of 16 in the 150-mg group (62%), and 3 of 7 in the 250-mg group (43%). None of
the subjects had a response in the placebo group. We observed significant improvements in
sodium transport, as measured by the basal and amiloride responses in the nasal potential
difference, in part 1 but not in part 2 of the study (Table 2 in the Supplementary Appendix).
The change in the sweat chloride concentration from baseline is shown in Figure 2 (the
actual sweat chloride concentrations at days 14 and 28 are shown in Fig. 4 in the
Supplementary Appendix). In part 1 of the study, the mean change in the sweat chloride
concentration from baseline to day 14 was −32.9 mmol per liter (95% CI, −42.4 to −23.3) in
the group that received 25 mg of VX-770, −40.4 mmol per liter (95% CI, −48.7 to −32.2) in
the group that received 75 mg of VX-770, and −42.3 mmol per liter (95% CI, −52.8 to
−31.8) in the group that received 150 mg of VX-770. The changes were significant
(P<0.001) in both within-subject comparisons and versus placebo in all VX-770 groups. The
mean change from baseline in the placebo group was 4.4 mmol per liter (95% CI, −10.4 to
19.1; P = 0.53). In part 2, the median change from baseline to day 28 was −59.5 mmol per
liter (range, −66.0 to −19.0) in the VX-770 150-mg group and −38.0 mmol per liter (range,
−47.0 to −10.5) in the VX-770 250-mg group. Results in both VX-770 groups were
significant for within-subject comparisons (P = 0.008 for VX-770 at a dose of 150 mg and P
= 0.02 for VX-770 at a dose of 250 mg) and versus placebo (P = 0.02 for the VX-770 150-
mg group and P = 0.03 for the VX-770 250-mg group). Over the same time frame, the
median change from baseline in the placebo group was 5.0 mmol per liter (range, −2.0 to
11.0; P = 0.38). Sweat chloride concentrations in the VX-770 treatment groups returned
toward baseline concentrations after the washout period in part 1 of the study (Fig. 3 in the
Supplementary Appendix). Considering parts 1 and 2 of the study together, after 14 days,
the number of subjects with available data who achieved the prespecified response criterion
of a decrease from baseline of 20 mmol per liter or more was 6 of 8 subjects in the VX-770
25-mg group (75%), 11 of 13 subjects in the VX-770 75-mg group (85%), 13 of 14 subjects
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in the VX-770 150-mg group (93%), and 4 of 7 subjects in the VX-770 250-mg group
(57%). No subjects had a response in the placebo group.
SPIROMETRIC ASSESSMENTS
Results of the absolute FEV1 in liters and the relative percentage change in the predicted
FEV1 are shown in Figure 3. Results of other spirometric measurements are provided in
Figures 5, 6, and 7 in the Supplementary Appendix. In part 1 of the study, at day 14, the
mean within-subject change in FEV1 from baseline was 0.09 liters (95% CI, −0.06 to 0.24)
in the VX-770 25-mg group, 0.19 liters (95% CI, 0.08 to 0.29) in the VX-770 75-mg group,
and 0.22 liters (95% CI, 0.08 to 0.36) in the VX-770 150-mg group. In the placebo group,
the mean change was −0.03 liters (95% CI, −0.20 to 0.15). Improvements in the VX-770
75-mg and 150-mg groups were significant for within-subject change (P = 0.003 and P =
0.006, respectively) and as compared with placebo (P=0.05 and P=0.04, respectively);
changes were not significant in the VX-770 25-mg group (P = 0.19 for the within-subject
change, P=0.28 vs. placebo) and placebo group (P=0.76 for the within-subject change).
Among the subjects who received VX-770, the mean relative change from baseline in the
percentage of predicted FEV1 was 4.9% (95% CI, −2.6 to 12.5) in the 25-mg group, 10.0%
(95% CI, 4.5 to 15.6) in the 75-mg group, and 10.5% (95% CI, 3.3 to 17.7) in the 150-mg
group. The mean change in the placebo group was 0.7% (95% CI, −8.8 to 10.2). Within-
subject improvements in the percentage of predicted FEV1 were significant in the VX-770
75-mg and 150-mg groups (P = 0.002 and P = 0.008, respectively), but not in the VX-770
25-mg or placebo groups (P = 0.18 and P = 0.88, respectively). Differences in comparisons
with the placebo group did not reach significance (P = 0.45, P = 0.09, and P=0.10,
respectively, for the VX-770 25-mg, 75-mg, and 150-mg groups).
In part 2 of the study, at day 28, the median within-subject change from baseline in FEV1
was 0.25 liters (range, 0.05 to 0.75) in the VX-770 150-mg group, 0.17 liters (range, 0 to
0.37) in the VX-770 250-mg group, and 0.20 liters (range, 0.12 to 0.33) in the placebo
group. The within-subject change was significant in both VX-770 treatment groups (P =
0.008 and P = 0.03 for 150 mg and 250 mg, respectively), but not in the placebo group (P =
0.38). Comparisons between the treatment and placebo groups were not significant (P = 1.0
and P = 0.65 for 150 mg and 250 mg of VX-770, respectively). The median relative change
from baseline in the percentage of predicted FEV1 was 8.7% (range, 2.3 to 31.3; within-
subject comparison, P = 0.008) in the VX-770 150-mg group and 4.4% (range, 0 to 18.3;
within-subject comparison, P=0.03) in the 250-mg group. In the placebo group, although
there was an improvement from baseline of 7.3% (range, 5.2 to 8.2), this difference did not
achieve statistical significance (within-subject comparison, P=0.13). Comparisons between
the treatment and placebo groups were not significant (P = 0.56 and P = 0.78 for 150 mg and
250 mg of VX-770, respectively).
The combined part 1 and part 2 data for the change from baseline to day 14 of study
treatment for spirometric analysis and CFTR biomarkers (nasal potential difference and
sweat chloride concentration) are shown in Figure 8 in the Supplementary Appendix.
HEALTH-RELATED QUALITY OF LIFE
The CFQ-R was administered in part 2 of the study only (Table 3 in the Supplementary
Appendix). No change from baseline in any CFQ-R domain was significant. After 14 days
of treatment, subjects reported median improvements from baseline in the respiratory
domain of 5.6 points (range, 0 to 16.7; P = 0.06 within-subject) in the VX-770 150-mg
group, 5.6 points (range, −11.1 to 11.1; P = 0.16) in the VX-770 250-mg group, and 2.8
points (range, −5.6 to 11.1; P = 0.75) in the placebo group. Comparisons between the
treatment and placebo groups were not significant (P = 0.61 and P = 0.71 for the VX-770
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150-mg and 250-mg groups, respectively). At day 28, the median improvements from
baseline were 8.3 points (range, 0 to 16.7; P=0.06 within-subject) in the VX-770 150-mg
group and 11.1 points (range, −5.6 to 33.3; P = 0.08) in the 250-mg group, whereas scores in
the placebo group were identical to those at day 14. Comparisons between the treatment and
placebo groups were not significant (P = 0.45 and P = 0.47 for the VX-770 150-mg and 250-
mg groups, respectively).
DISCUSSION
This randomized, double-blind, placebo-controlled, multicenter trial of oral VX-770
involved subjects with cystic fibrosis and the G551D mutation on at least one allele. The
primary end points of the study were safety and the adverse-event profile associated with
treatment. No subject withdrew from the study, and the frequency of adverse events was
similar between the study groups. The safety profile of VX-770 in this study provides
support for further clinical evaluation. In addition, VX-770 was associated with within-
subject improvements in CFTR ion-channel function in the nasal epithelium and sweat
glands and within-subject improvements in lung function, suggesting a potential clinical
benefit. The findings in the nasal potential difference and sweat chloride biomarkers
associated with VX-770 are consistent with improved CFTR ion-channel function. Previous
studies of agents aimed at improving CFTR function, including oral and topical drug
candidates as well as topically applied gene-therapy vectors, showed improvement in
measures of chloride transport in the nasal potential difference,14–17 but they did not
measure sweat chloride concentrations. Single-center studies of oral lithium and of
intravenous gentamicin have shown decreases in sweat chloride concentrations.18,19 The
study of gentamicin also showed an improvement in the nasal potential difference.19 The
current placebo-controlled, multicenter trial showed within-subject improvement in both the
nasal potential difference and sweat chloride concentrations. Administration of VX-770
resulted in a much greater reduction in sweat chloride levels than has been observed with
other compounds; sweat chloride levels in some subjects were outside the diagnostic range
for cystic fibrosis after VX-770 treatment.
VX-770 was associated with a modest but significant within-subject improvement in lung
function after 14- and 28-day treatment regimens. Improvement at day 28 in the groups of
subjects who received VX-770 was similar to that at day 14, and the improvements were
statistically significant within the treatment group. The change in FEV1 was not significant
among subjects who received placebo in part 1 and part 2 of the study; however, the lack of
significance should be interpreted with caution considering the small sample size within
these groups. The reason for numerical improvement in some subjects who received placebo
in part 2 is unclear and could be related to improved adherence to concomitant therapies
within the clinical-trial setting. In addition to lung function, an improvement in the
respiratory symptoms domain of the CFQ-R was observed in the groups of subjects who
received VX-770; this improvement exceeded the minimal clinically important difference
for this domain,13 although the improvements did not reach statistical significance. It is not
known to what extent lung function can be improved in persons with cystic fibrosis in the
long term and how changes in spirometric measures over the short term may reflect long-
term disease progression.
The marked magnitude of the effect of VX-770 on sweat chloride concentration, as
compared with the nasal potential difference and pulmonary function, may be explained by
physiological differences between the sweat gland, where CFTR is involved in chloride
absorption, and the airway, where CFTR is involved in chloride secretion. The variability in
the end-point measures and the statistical limitations within this small study also probably
contributed to the differences between outcome measures. It is not known whether there are
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important interindividual differences in responses to VX-770, and the biomarker and clinical
responses in large groups of subjects have not been confirmed.
We did not investigate the mechanism by which VX-770 affects the airway surface and
respiratory symptoms. VX-770 is known to improve CFTR-mediated ion transport and to
reduce surface liquid absorption in cultured human bronchial epithelial cells,8 so it may have
similar effects in vivo. Improvement in mucus clearance through better hydration of the
airway surface could ameliorate airway obstruction by decreasing mucus plugging.
In summary, VX-770, an oral potentiator of CFTR in vitro, was associated with few severe
side effects in this clinical evaluation. Some secondary end points showed no statistically
significant differences versus placebo, although we observed significant within-subject
improvements in respiratory (nasal potential difference) and nonrespiratory (sweat chloride
concentration) biomarkers of CFTR function and improvements in lung function
(spirometric assessment). The effects of VX-770 on CFTR-mediated ion transport and lung
function suggest that the improvement of CFTR function may be a viable therapeutic
approach in cystic fibrosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Measurements of the Nasal Potential Difference
Panel A shows the mean nasal potential difference (in response to the administration of a
chloride-free isoproterenol solution) at baseline and day 14 during part 1 of the study in each
of the four study groups. The I bars indicate the ranges, and the dashed line indicates no
response. Panel B shows the mean nasal potential difference at baseline, day 14, and day 28
during part 2 of the study in each study group. The I bars indicate the ranges, and the dashed
line indicates no response. Panel C shows the change in the nasal potential difference from
baseline to day 14 in individual subjects (indicated by symbols) in each study group and the
least-squares means (indicated by solid lines) from the mixed model in part 1 of the study.
The dashed line indicates no change. Panel D shows the change in the nasal potential
difference from baseline to day 14 or day 28 in individual subjects (indicated by symbols) in
each study group and the medians (indicated by solid lines) in part 2 of the study. The
dashed line indicates no change. P values are for within-subject comparisons.
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Figure 2. Measurements of Sweat Chloride Concentration
Panel A shows the mean sweat chloride concentration at baseline and days 7 and 14 during
part 1 of the study for each study group. The I bars indicate the ranges. Panel B shows the
mean sweat chloride concentration at baseline and days 3, 14, 21, and 28 during part 2 of the
study for each study group. The I bars indicate the ranges. The dashed lines in Panels A and
B indicate the lower limit of abnormal sweat chloride concentrations. Panel C shows the
change in the sweat chloride concentration from baseline to day 14 in individual subjects
(denoted by symbols) in each study group and the least-squares means (indicated by solid
lines) from the mixed model in part 1 of the study. P<0.001 for all comparisons (within-
subject and vs. placebo). The dashed line indicates no change. Panel D shows the change in
the sweat chloride concentration from baseline to day 14 or day 28 in individual subjects
(symbols) in each study group and the medians (indicated by solid lines) in part 2 of the
study. At day 14, in the VX-770 150-mg group, P = 0.02 for within-subject comparisons and
P = 0.03 versus placebo. In the VX-770 250-mg group, P = 0.02 for within-subject
comparisons and P = 0.05 versus placebo. At day 28, in the VX-770 150-mg group, P =
0.008 for within-subject comparisons and P = 0.02 versus placebo. In the VX-770 250-mg
group, P = 0.02 for within-subject comparisons and P = 0.03 versus placebo. The dashed
line indicates no change.
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Figure 3. Measurements of Pulmonary Function
Panel A shows the mean change from baseline to day 14 in the forced expiratory volume in
1 second (FEV1) during part 1 of the study in each study group. In the VX-770 150-mg
group, P = 0.006 for within-subject comparisons and P = 0.04 versus placebo. In the
VX-770 75-mg group, P = 0.003 for within-subject comparisons and P = 0.05 versus
placebo. The I bars indicate the ranges. Panel B shows the median FEV1 change from
baseline during part 2 of the study in each study group. In the VX-770 250-mg group, P =
0.02 for within-subject comparisons for all time points shown except for day 28, when P =
0.03 for within-subject comparisons. In the VX-770 150-mg group, P = 0.05 for within-
subject comparisons at day 3 and P = 0.008 for within-subject comparisons at days 14, 21,
and 28. The I bars indicate the ranges. Panel C shows the relative change from baseline in
the percentage of predicted FEV1 from baseline to day 14 in individual subjects (indicated
by symbols) in each study group and the least-squares means (indicated by solid lines) from
the mixed model in part 1 of the study. In the VX-770 75-mg group, P = 0.002 for within-
subject comparisons, and in the VX-770 150-mg group, P = 0.008 for within-subject
comparisons. Panel D shows the relative change in the percentage of predicted FEV1 from
baseline to day 14 and day 28 in individual subjects (indicated by symbols) in each study
group and the medians (indicated by solid lines) in part 2 of the study. At day 14, in the
VX-770 150-mg group, P = 0.008 for within-subject comparisons. In the VX-770 250-mg
group, P = 0.02 for within-subject comparisons. At day 28, in the VX-770 150-mg group, P
= 0.008 for within-subject comparisons. In the VX-770 250-mg group, P = 0.03 for within-
subject comparisons. In all four panels, the dashed lines indicate no change from baseline.
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